Hippocratic AI has raised $126 million in a Series C funding round, bringing its valuation to $3.5 billion and total funding to $404 million. Led by Avenir Growth with participation from General Catalyst, Kleiner Perkins, Premji Invest, and WellSpan Health, the investment will support the global expansion of Hippocratic AI’s clinically safe generative AI agents. In just 15 months since launch, the company has partnered with over 50 health systems, payers, and pharmaceutical firms across six countries, developed more than 1,000 clinical use cases, and completed 115 million patient interactions without safety incidents.
Avenir Growth’s Andrew Sugrue praised Hippocratic AI’s leadership in “agentic healthcare” and its rigorous safety focus, noting that the company has become a trusted choice among healthcare executives. CEO Munjal Shah emphasized that the funding will accelerate deployments, advance the firm’s Polaris Safety Constellation Architecture, and support strategic mergers and acquisitions. He reiterated Hippocratic AI’s mission to bring “an era of abundance” to healthcare by combining scalable AI capabilities with a steadfast commitment to patient safety and real-world clinical reliability.